Craig Fox
Directeur Technique/Scientifique/R&D chez C4X Discovery Ltd.
Postes actifs de Craig Fox
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
C4X Discovery Ltd.
 C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Directeur/Membre du Conseil | - | - |
| Directeur Technique/Scientifique/R&D | - | - | |
Oxford Science Enterprises PLC
 Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Private Equity Investor | 01/02/2022 | - |
Historique de carrière de Craig Fox
Anciens postes connus de Craig Fox
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| C4X DISCOVERY HOLDINGS PLC | Directeur/Membre du Conseil | 22/11/2016 | 31/03/2022 |
| Directeur Technique/Scientifique/R&D | 01/10/2015 | 31/03/2022 | |
Pulmagen Therapeutics LLP
 Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Corporate Officer/Principal | - | 01/01/2010 |
Formation de Craig Fox
| University of Birmingham | Doctorate Degree |
| University of Surrey | Undergraduate Degree |
Statistiques
Internationale
| Royaume-Uni | 7 |
Opérationnelle
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
| Doctorate Degree | 1 |
Sectorielle
| Health Technology | 4 |
| Consumer Services | 3 |
| Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| C4X DISCOVERY HOLDINGS PLC | Health Technology |
| Entreprise privées | 3 |
|---|---|
Pulmagen Therapeutics LLP
Pulmagen Therapeutics LLP Pharmaceuticals: MajorHealth Technology Pulmagen Therapeutics Ltd. manufactures and develops respiratory drugs. Its services include pulmagen respiratory product pipeline, pulmagen crth2 antagonist product pipeline, new generation bronchodilators-astrazeneca collaboration, theocort-inhaled corticosteroid re-sensitisation, inhaled ppar gamma agonists and chiesi collaboration-anti-inflammatory agents. The company was founded in February 2010 and is headquartered in Slough, the United Kingdom. | Health Technology |
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |
Oxford Science Enterprises PLC
Oxford Science Enterprises PLC Investment ManagersFinance Oxford Science Enterprises PLC (Oxford Science Enterprises) is a venture capital firm founded in 2015. The firm is headquartered in Oxford, United Kingdom. | Finance |
